The advent of anti-PD-L1 immunotherapies have significantly improved the treatment landscape of triple-negative breast cancer (TNBC). Philippe Georges Aftimos, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of current advances in the uses of targeted therapies for TNBC, including the recent approval of sacituzumab govitecan, an antibody–drug conjugate (ADC). Dr Aftimos additionally highlights novel PARP inhibitors, targeting BRCA1/2, as well as novel targets such as NOTCH. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.